Does size or speed of a shot affect pain? a trial investigates
NCT ID NCT07769489
First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time
Summary
This study tests how different volumes and speeds of subcutaneous injections (up to 5 mL) affect pain and tolerability compared to standard practice. Healthy adults aged 18-64 will receive saline injections via a syringe pump, with the order of injection settings assigned by chance. Participants will be involved for about one week, and researchers will measure pain using a visual scale, along with other factors like injection site reactions.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Syringe pump device delivering saline solution subcutaneously
- What this could lead to
- If successful, this could help design less painful injection methods for large-volume medications, improving patient comfort and adherence.
- What could go wrong
- This is an early-phase exploratory study in healthy volunteers, so results may not apply to real-world patients or specific drugs. Pain is subjective and varies widely among individuals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 64 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Healthy male or female participants as judged by the investigator. * Age 18-64 years (both inclusive) at the time of signing the informed consent. * Body Mass Index (BMI) greater than or equal to (\>=) 18.5 and less than or equal to (\<=) 30.0 kilograms per square metre (kg/m\^2) (both included). * White (Light skin that allows for adequate medical evaluation of any skin reactions). Exclusion criteria: * Known or suspected hypersensitivity to study intervention(s) or related products. * Previous randomisation in this study. * Previous rescreening for this study. * Pregnant or breastfeeding female participants. * Current participation (i.e., signed informed consent) in any other interventional clinical study. Treatment with an investigational medical product within 3 months or 5 half-lives (if known), whichever is longer prior to screening. * Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol, including insufficient abdominal area for injection. * Intake of any medication that could influence pain perception or injection site reaction appearance (e.g., anti-coagulants, including low dose of aspirin, systemic antihistamines, pain-relieving, or anti-inflammatory medicinal products) within the last week before the intervention. * Intake of alcohol within the last 24 hours (self-reported) or a positive result of alcohol breath test prior to randomisation and intervention. * Intake of illicit drugs within the last 48 hours (self-reported) or a positive result of urine drug screening prior to screening. * Use of any nicotine products within the past month before screening. * Known active or inactive skin condition or disease, tattoos, or other interventions in the injection area that may affect pain perception or assessment of injection-site reactions. * Strenuous exercise within 3 days prior to the intervention.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy participants are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Novo Nordisk Clinical Innovation Centre A/S
Gentofte Municipality, 2820, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Will a cheaper blood thinner work the same as xarelto?
- Can a CBD and THC mix pave the way for a new migraine therapy?
- Can a common fungal drug change how a new cancer drug acts?
- Can a pill tame obesity? new oral drug heads to early human tests
- Can a copycat drug match Dupixent's effects?
- Snack bars as a secret weapon against hunger?